Mirati Therapeutics (MRTX) PT Raised to $225 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Mirati Therapeutics (MRTX) Prices 4.33M Share Common Offering at $202/Sh
October 28, 2020 5:57 AM EDTMirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $800.0 million, before... More
Mirati Therapeutics (MRTX) PT Raised to $210 at Piper Sandler
October 26, 2020 8:24 AM EDTPiper Sandler analyst Tyler Van Buren raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $210.00 (from $170.00) while maintaining an Overweight rating.
The analyst commented, "The adagrasib (formerly MRTX849) Phase Ib/II 45% ORR met investor expectations perour recent flash poll and appears improved versus... More
